Summary.-The steroids prednisolone and progesterone significantly altered the therapeutic indices of the alkylating agents, nitrogen mustard, melphalan, cyclophosphamide, phenyl acetic mustard and chlorambucil. For nitrogen mustard, chlorambucil and phenyl acetic mustard, prednisolone reduced host toxicity in the rat and enhanced the antitumour effectiveness against alkylating-agent-resistant strains of the Yoshida sarcoma and Walker carcinosarcoma. Progesterone also increased the therapeutic index of chlorambucil in the rat by decreasing its systemic toxicity.
diseases, alkylating agents, intercalating antibiotics, antimetabolites and Vinca alkaloids are often used in combination (Ziegler et al., 1972; Tucker et al., 1968; Bodey et al., 1973) . However, the refractive nature of many tumours, and the heterogeneity of their drug sensitivity, has necessitated the use of increasingly high doses of drugs to achieve a tumour response. The margin of tolerance between tumour response and the systemic toxicity to the host has therefore narrowed. The use of pretreatment with cyclophosphamide (Hedley et al., 1978) and marrow autotransplantation (McElwain et al., 1979) have been used successfully in combination with high-dose melphalan, but there is a clear need for other approaches to widen the therapeutic gap.
We have previously shown that prednisolone is able to improve the therapeutic index of chlorambucil in an experi-* To whom all correspondence should be addressedl. mental tumour system (Harrap et al., 1977) . Host toxicity was reduced and tumour-cell kill maintained. Further, a tumour with acquired resistance which was refractory to chlorambucil alone responded to the combined treatment. Prednisolone is frequently included in clinical treatment schedules especially for tumours of the lympho-proliferative system, where tumoricidal effects could be expected from the corticosteroid alone (Scavino et al., 1976; Land et al., 1976; Whitecar et al., 1972) . In our experimental system, however, the tumour did not respond to prednisolone alone (Harrap et al., 1977) . In view of the extensive clinical use of alkylating drugs we thought it important to determine whether the enhanced therapeutic index in a nonsteroid-responsive tissue could be extended to other alkylating agent/steroid combinations or whether it was a property peculiar to chlorambucil.
We now present data on the toxicity and antitumour activity of a number of alkylating agent/steroid combinations in 2 different experimental tumour systems in vivo. An abstract of preliminary results of this study has already been published (Harrap & Hill, 1969) . The resistant strain of the Walker carcinosarcoma was developed in vitro by repeated CHL treatments (Tisdale & Phillips, 1976) and both sensitive and resistant Walker tumours were passaged as ascites tumours as described for the Yoshida tumour. The ADJ/PC6A plasmacytoma was maintained as a solid tumour passaged s.c. every 21 days by trochar as a 1mm3 implant fragment (Connors et al., 1972) .
Antitumour studies and drug treatments.-For antitumour studies on the Yoshida sarcoma the cells in the peritoneal cavity were counted each day for 3 days after drug treatments, as previously described (Harrap & Hill, 1969) . Drugs were administered s.c. in the back of the neck 3 days after tumour implant. Studies on the Walker tumour were performed in two ways. The tumour was injected i.p. as an ascites and cells counted for 3 days, as for the Yoshida tumour. In these cases rats received s.c. drug treatments in the back of the neck. Or the Walker tumour cells were injected i.m. in one hind leg, where a solid tumour developed. The untreated tumour grew to a weight of 9-10 g in 8 days. The weight of tumour in the drug-treated animals was compared with that of the untreated controls 8 days after tumour implant. Rats bearing the solid tumours were treated i.p. or s.c. one day after tumour implant (Rosenoer et al., 1966) . The ADJ/PC6A tumour was implanted s.c. in the flank, and drug treatments were given i.p. 24 days later. The weights of tumour in drug-treated and control mice were compared 10 days after drug treatment, when the untreated tumours weighed 8-9 g (Connors et al., 1972) . CHL and PRED were dissolved in dimethyl sulphoxide (DMSO) , MEL in ethanolic HCl-phosphate, propylene glycol (Harrap & Hill, 1969) and CY and PROG in 0.9% NaCl. The steroids were always given in equimolar doses to those of the alkylating agent, because this combination had proved effective in the form of the steroid ester prednimustine, which is inactive until hydrolysed to its component molecules Harrap et al., 1977) .
RESULTS
In the rat, the systemic toxicity of either HN2 (Fig. 1) or PAM (Table I) was reduced if the alkylating agent was administered in combination with PRED. Fig. 1 details the systemic toxicity following a dose of 1 mg/kg of HN2, but no deaths occurred if this was accompanied by an equimolar (3 mg/kg) dose of PRED. The steroid was equally effective if given simultaneously with HN2 or 4 h later. Similar toxicity studies (Newell et (Rosenoer et al., 1966 way (Table II) . The greatest tumour response was when the steroid was given 4 h after the alkylating agent. Similar schedule dependency has been described for the CHL/PRED combination (Harrap et al., 1977) . Fig. 2 shows the potentiation by PRED of the antitumour effect of HN2. A significant decrease in the growth rate of the resistant Walker tumour was achieved, and the response of the sensitive tumour was not compromised. A similar response was obtained in the sensitive and resistant lines of the Yoshida sarcoma (data not shown). Because of the reduced toxicity of the combination it was possible to use up to 1 mg/kg of HN2 rather than 0-8 mg/kg, which is the maximum tolerated dose of the single agent. Table I. t Because the mol. wt of PRED is 1/3 more than that of CY, the dose of PRED used was 1/3 more in mg/kg i.e. 30 and 40 mg/kg for CY and PRED respectively.
Combinations of CY or MEL with PRED were more toxic than the alkylating agents alone, and this was also schedule-dependent. Table III shows that PRED decreased the LD50 and the ED99 of CY if it was given 4 h before or after CY. The greatest response in the resistant tumour was obtained when the steroid was given 4 h after CY. For both sensitive and resistant tumours the simultaneous administration of CY and PRED had the lowest therapeutic index.
The antitumour activity of MEL against a sensitive mouse tumour was not enhanced by combination with PRED, though its toxicity was increased, thus lowering the TI (Table IV) . In the rat, toxicity was also increased when measured by body-weight loss and animal deaths (Fig. 3) . MEL alone had an LD50 of 12 mg/kg, whereas the combination of MEL and PRED simultaneously produced an LD50 of 5-6 mg/kg. (Harrap et al., 1977 (Bondy, 1969) . Walker tumours, we have shown that id to mimic the effects after treatment with a combination of cilng CHL toxicity in the i)nThere wslittle effct alkylating agent and steroid there was a . The waseiti e eWlecr greater stimulation of DNA cross-linking fThe sensidoled WaLkr and nuclear-protein phosphorylation than TI was doubled. CHL after treatment with the alkylating agent ximum tolerated dose of alone (Wilkinson et al., 1979 proved effective in combination with alkylating agents for the treatment of lymphomas (Jelliffe, 1975) and leukaemias (Han et al., 1973) . In these cases the steroid alone is cytotoxic. MEL can also be potentiated in vivo by cobra-venom cytotoxin P6 (Braganca & Hospattankar, 1978) but again the venom is toxic when used alone. The antitumour efficacy of HN2 against a human cell line has been potentiated by combining it with nontoxic doses of warfarin (Dolfini et al., 1980) . However, the systemic toxicity of this combination was not reported. We have potentiated alkylating-agent activity against resistant tumour cells by noncytotoxic doses of steroid, and in the cases of HN2, CHL and PAM, without increased systemic toxicity. The modulation of the systemic toxicity of alkylating agents by steroids cannot at present be explained, but is probably not linked to altered pharmacokinetics, since PRED does not appear to alter the pharmacokinetics of CHL (Newell et al., 1981) . The enhanced toxicity of MEL and CY, but reduced toxicity of HN2, CHL and PAM may reflect differences in the modes of action of the individual alkylating drugs. For example, MEL is actively transported (Redwood & Colvin, 1980) but CHL enters by passive diffusion (Hill et al., 1971) . The kinetics of DNA crosslinking induced by MEL and HN2 are different (Ross et al., 1978; Brox et al., 1980) : CY has a greater therapeutic effect on experimental autoimmune disease than does CHL (Gerber et al., 1977) and the replacement of HN2 by CHL in the schedule for Hodgkin's disease resulted in similar tumour-cell kill but reduced normal-tissue toxicity (McElwain et al., 1977 ). It appears, therefore, that although these alkylating agents kill dividing rather than resting cells (Van Putten & Lelieveld, 1971) , there are subtle differences in the spectra of their normal-tissue toxicities which are enhanced by the steroid.
The ability of PROG to suppress CHL toxicity in the rat, as does PRED (Harrap et al., 1977) , further supports the theory of a general corticosteroid response, since PROG is a precursor for both cortisol and corticosterone (Bondy, 1969) . Coincidentally, in a case of inadvertant CHL overdose, the patient took prednisone (80 mg/day) together with the CHL (56 mg/day) for 5 days and sustained only moderate pancytopenia, which quickly recovered (Enck & Bennett, 1977) . Possibly the presence of the steroid contributed towards this low toxicity.
Diurnal variations in marrow response (Simpson & Stoney, 1977) or plasma binding of drug (Hill & Harrap, 1972) , amongst other factors, influence alkylating-agent toxicity, and these might be modified by steroids. PRED binds to plasma proteins and may modify plasma binding of alkylating agents (El Dareer et al., 1977) . Corticosteroids have an inhibitory effect on protein and nucleic-acid synthesis in lymphoid tissues and inhibit protein synthesis in muscle, s.c. tissue and the bone matrix (Kornel, 1973) . These many different properties can be modified by alkylating agents, e.g. the inhibition of glucocorticoid response in the rat by CY (Burroughs & Cidlowski, 1978) . The ability of corticosteroids to cause selective redistribution of circulating lymphocytes (Fauci, 1975; Fauci & Dale, 1974; Cohen, 1972) could possibly modulate alkylating-agent toxicity. Indeed such a mechanism could explain the effects of methyl prednisolone in combination with CY, which increased the colony-forming units in mouse marrow and spleen compared with CY alone (Joyce & Chervechick, 1977) . Anabolic effects of PRED, such as its stimulation of RNA synthesis (Kornel, 1973) may also modify host toxicity.
Steroids are already used to treat lymphoid tumours, where prednisone alone is effective, and to treat breast carcinoma. Here again there is experimental evidence for cytotoxicity of the steroid alone (Braunschweiger et al., 1978) . We would suggest that our antitumour and hosttoxicity data indicate that the inclusion of prednisolone in some clinical treatment schedules using chlorambucil or nitrogen mustard might be beneficial.
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